Protocol
11-208
Full Title
A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Purpose
Cytarabine and etoposide are drugs commonly used to treat pediatric leukemia. Plerixafor is a drug used to promote the movement of stem cells from the bone marrow into the blood stream before a stem cell transplant. By mobilizing leukemia stem cells from the bone marrow, researchers believe that plerixafor may be useful as a “chemosensitizing” agent that may make treatment with cytarabine and etoposide more effective.
The goal of this study is to find the highest dose of plerixafor that can be given safely with cytarabine and etoposide in children with acute leukemia or myelodysplastic syndrome (MDS) that has returned or persists despite prior therapy. This study is being conducted by POETIC (Pediatric Oncology Experimental Therapeutics Investigator Consortium) and the AFLAC Cancer Center and Blood Disorders Service.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or MDS that has returned or persists despite prior therapy.
- Patients must be at least age 3 but younger than age 30.
- Patients must have recovered from the side effects of prior treatment.
For more information about this study and to inquire about eligibility, please contact Dr. Tanya Trippett at 212-639-8267.
Disease(s)
Hematology: Myelodysplastic Syndrome
Leukemia
Leukemia: Acute Lymphoblastic Leukemia
Leukemia: Acute Myelogenous Leukemia
Leukemia: Myelodysplastic Syndrome
Locations
Related Diseases
